The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | A Phase II study of low-dose subcutaneous decitabine in myelofibrosis
In this video, Olatoyosi Odenike, MD, University of Chicago, Chicago, IL, briefly comments on a multicenter Phase II trial (NCT00095784) that investigated the use of low-dose subcutaneous decitabine in patients with myelofibrosis (MF). Prof. Odenike highlights that the results of this trial validate the use of hypomethylating agents (HMAs) in this disease and demonstrate that alternative methods of administering decitabine are feasible. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I believe that this multi-center study validated this approach of using DNA methyltransferase inhibitors, otherwise known as hypomethylating agents in advanced-phase MPNs, specifically myelofibrosis, including myelofibrosis that’s progressing towards the accelerated phase. It also highlights the fact that decitabine can be delivered in other ways besides the standard intravenous formulation...
I believe that this multi-center study validated this approach of using DNA methyltransferase inhibitors, otherwise known as hypomethylating agents in advanced-phase MPNs, specifically myelofibrosis, including myelofibrosis that’s progressing towards the accelerated phase. It also highlights the fact that decitabine can be delivered in other ways besides the standard intravenous formulation. And I’m very excited that oral decitabine is actually now also entering new investigational trials for advanced-phase MPNs. So I think the future holds a lot of promise.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
